Navigation Links
Moffitt Cancer Center signs licensing agreement with Proteacel, LLC
Date:3/18/2010

Tampa, FL (March 18, 2010) Moffitt Cancer Center and Proteacel LLC announced today that they have entered a licensing agreement under which Proteacel has acquired the exclusive rights to the PORE technology for delivery of genes into cells.

Genes are the instructions that build cells. Defects in these genes cause disease, such as cancer. In order to understand how these genes work and their involvement in a disease process, researchers must study and modify them. The most common way to study gene function is to transfer the gene into cells. Transfection is the process of introducing foreign DNA, or genes, into cells. This fundamental process is critical in conducting medical research. However, low rates of transfection and high levels of cell death currently create bottlenecks.

Under the direction of Dr. Deepak Agrawal, Moffitt researchers have developed a proprietary technology that dramatically improves the functionality and performance of transfection technology. The patented Perforation Optimization and Repair Enhancement, or PORE, solves a number of immediate problems in the use of transfection by creating a higher level of efficiency and cell viability. This is particularly valuable for stem cells and primary cells that are the most medically relevant and the most difficult to transfect.

"I am very pleased that the PORE technology will be made available to researchers throughout the world," Agrawal said. "We believe PORE will fuel biological discovery by allowing more effective use of stem cells and primary cells for research, drug discovery and development of cell therapies."

"Proteacel's initial business activity will have Proteacel contracting to transfect specific hard to transfect cell lines with identified DNA," said Dr. Joseph Zendegui, president and chief operating officer of Proteacel. "Target customers for this service will be academic institutions and biotechnology companies in the biomedical research field. Using PORE as our technology base, we will expand our efforts into development and commercialization of drug discovery, cell differentiation assays."

"We are excited to see this technology move from the research labs here at Moffitt Cancer Center into the capable hands of Proteacel for the continuation of its development," said Ray Carpenter of Moffitt's Office of Technology Management and Commercialization. "Further, our office will remain focused on bridging entrepreneurs and Moffitt's faculty to cultivate local start-up company opportunities."

Under the terms of the License Agreement, Proteacel will pay Moffitt license fees, milestone payments and royalties on sales of PORE products and services.


'/>"/>

Contact: Michelle Foley
Michelle.Foley@moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related biology news :

1. Could regulating intestinal inflammation prevent colon cancer?
2. Blocking cancer in its path: New cellular defect discovered
3. UAB oncologists: HPV vaccine protects from cancer recurrence
4. 2 at 1 stroke -- how cells protect themselves from cancer
5. 5th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded
6. A golden bullet for cancer
7. Preventing gastric cancer with antibiotics
8. Berkeley scientists find new way to get physical in the fight against cancer
9. VAI researchers develop tool to help study prostate cancer
10. LSUHSC researcher finds first inherited prostate cancer genetic mutation in African-American men
11. Breast cancer drug fulvestrant appears more effective in the presence of CK8 and CK18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2016)... DUBLIN , January 13, 2016 ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the ... & Identification Market - Estimation & ...
(Date:1/11/2016)... 11, 2016  higi, the leading retail and ... locations, web and mobile, today announced it has ... existing investors. --> ... further innovate higi,s health platform – its network ... – including expanding services and programs to retail ...
(Date:1/8/2016)... January 8, 2016 NXTD ), ... WorldVentures ® , a privately held leading direct seller ... Inc. 5000 fastest-growing company announced that on December ... $2 million in Nxt-ID to develop a proprietary new ... Wocket ® , a unique smart wallet that serves ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... Charlotte, NC (PRWEB) , ... February 10, 2016 ... ... highly anticipated expansion to their comprehensive training and support program, Sonalinkā„¢ remote monitoring. ... Sonablate® HIFU procedures performed on Friday, February 5th, connecting Dr. Samuel Peretsman to ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... current winner of the Highest Overall Customer Rating Award from Circuits Assembly , ... business units across the USA, Canada, Mexico and China. , The EMS provider, ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... on its free and validated Electronic Data Capture (EDC) system ClinCaptureand its new ... Clinical Trials West Coast 2016 Conference in San Mateo, California on February 10th ...
(Date:2/9/2016)...  DNAtrix, a clinical stage, biotechnology company ... its lead product, DNX-2401, has been designated ... medicinal product for the treatment of glioma. ... approximately 25,000 people a year in the ... --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
Breaking Biology Technology: